secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001104659-26-009495
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge
--------------------------------------------------------------------------------

- Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).
- Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).
- KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).
- FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.
- Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/0001104659-26-009495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-009495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer